Leading healthcare professionals will discuss the scientific evidence for and against the use of aspirin for the chemoprevention of cancer.
With the rising importance of disease prevention as a key pillar for controlling the escalating costs of healthcare, researchers are looking at how aspirin may provide an important addition to other medical approaches to address the challenge.
The symposium, sponsored by the CSIRO and Monash University, will hear from world-leading researchers working in the field of aspirin and cancer prevention.
Professor Carlo Patrono from the Catholic University, Rome, is the keynote speaker for the event and he will discuss the mechanisms of action by which aspirin may have its protective effect.
Those attending will also learn of the advantages and drawbacks of regular aspirin consumption, and how these impact on aspirin’s current and future use in cancer prevention and management.
Other topics to be discussed will be the cost benefit of aspirin-based cancer chemoprevention.
The Aspirin Reducing Events in the Elderly (ASPREE) clinical trial led by Monash University and the University of Minnesota, and its associated Healthy Ageing Biobank developed under CSIRO’s Flagship Collaboration Clusters program, will also be outlined.
Cutting Edge Symposium: Aspirin and Cancer Prevention, is on Monday 20 October 2014 at AMREP Lecture Theatre, Alfred Hospital, 75 Commercial Rd, Melbourne from 8.15am-5pm.
To register for the event go to: http://www.csiro.au/Outcomes/Health-and-Wellbeing/Prevention/Aspirin-and-Cancer-Prevention.aspx